https://scholars.lib.ntu.edu.tw/handle/123456789/481092
標題: | Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery | 作者: | JANG-MING LEE Yang S.-Y. Yang P.-W. CHIA-TUNG SHUN Wu M.-T. CHIH-HUNG HSU CHIA-CHI LIN CHIA-HSIEN CHENG Wang Y.-H. Chuang T.-H. JIN-SHING CHEN HSAO-HSUN HSU PEI-MING HUANG SHUENN-WEN KUO Lee Y.-C. |
公開日期: | 2011 | 卷: | 18 | 期: | 7 | 起(迄)頁: | 2066-2073 | 來源出版物: | Annals of Surgical Oncology | 摘要: | Background. The EGFR gene has been demonstrated to be an important factor influencing treatment response for various cancers, and its expression has been shown to be modified by the polymorphic CA repeat length at the 5′ regulatory sequence in intron 1. We investigated whether this EGFR polymorphism is associated with prognosis in patients with esophageal cancer after concurrent chemoradiotherapy (CCRT) and esophagectomy. Methods. A cohort of 148 patients with esophageal cancer received cisplatin-based CCRT (concurrently combined with 40 Gy irradiation) and subsequent esophagectomy. Their EGFR genotypes were determined by polymerase chain reaction from leukocyte DNA, which was obtained before treatment and was correlated with patient survival. Results. Patients with the homozygous short allele (<20 CA) of the EGFR gene in intron 1 were more likely to have a shorter duration of survival after CCRT and surgery than those with the homozygous long allele [adjusted hazard ratio (HR) (95% confidence interval [CI]) of death: 1.88 (1.02-3.49); P = 0.045]. This unfavorable prognostic effect of EGFR homozygous short CA repeat was mainly manifested in patients with good response to CCRT [adjusted HR (95% CI) of death 3.40 (1.06-10.89); P = 0.039]; it was less evident in those with poor response to CCRT [adjusted HR (95% CI) 1.40 (0.65-3.02); P = 0.384]. Conclusions. The EGFR CA repeat genetic polymorphism may act as a valuable molecular predictor of clinical outcome of esophageal cancer after CCRT and esophagectomy, especially in those with good response to CCRT. ? Society of Surgical Oncology 2011. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-80051550539&doi=10.1245%2fs10434-011-1559-9&partnerID=40&md5=27cfdf2c3c5f3cc97ae9d70cdc1baa88 https://scholars.lib.ntu.edu.tw/handle/123456789/481092 |
ISSN: | 1068-9265 | DOI: | 10.1245/s10434-011-1559-9 | SDG/關鍵字: | cisplatin; DNA; epidermal growth factor receptor; adult; allele; article; cancer patient; cancer surgery; cancer survival; chemoradiotherapy; esophagus cancer; esophagus resection; genetic association; genotype; human; intron; leukocyte; major clinical study; prognosis; protein polymorphism; treatment response; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; DNA, Neoplasm; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Introns; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Receptor, Epidermal Growth Factor; Survival Rate |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。